Aplindore

Drugbox
IUPAC_name = (2S)-2- [(phenylmethylamino)methyl] -2,3,7,9-tetrahydro- [1,4] dioxino [3,2-e] indol-8-one


CAS_number= 189681-71-8
ATC_prefix=
ATC_suffix=
ATC_supplemental=
PubChem= 6440763
DrugBank=
C = 18 | H = 18 | N = 2 | O = 3
molecular_weight = 310.346 g/mol
smiles = c4ccccc4CNCC(CO2)Oc1c2ccc(N3)c1CC3=O
bioavailability=
protein_bound =
metabolism =
elimination_half-life=
excretion =
licence_EU =
pregnancy_category =
legal_UK =
routes_of_administration=

Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the Dopamine receptor D2. [Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G, Popiolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. "European Journal of Pharmacology". 2006 Dec 15;552(1-3):36-45. PMID 17056032] It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome. [ [http://www.pharmaceutical-business-review.com/article_news.asp?guid=E6E77319-B0D6-4E6A-9288-DD43A553D2F9 Neurogen licenses Aplindore from Wyeth] ]

References